avapritinib
Blueprint Medicines Inks $1.25B Financing Deal in Exchange for Royalties of Ayvakit, Gavreto
Sixth Street is providing funds in exchange for future royalties of Ayvakit and the KIT D816V inhibitor BLU-263, while Royalty Pharma inked a similar deal for Gavreto.
Blueprint Medicines' Q1 Ayvakit Sales More Than Triple
In Q1, the precision treatment for GIST and systemic mastocytosis brought in $23.8 million compared to $7.1 million in the year-ago period.
Blueprint Medicines Reports $107M in Q4 Revenues Helped by Growing Ayvakit Sales
The company expects Ayvakit revenues to more than double in 2022, and projected sales in the range of $115 million to $130 million.
CStone, Blueprint Medicines' Ayvakit Nets Hong Kong Approval for Biomarker-Defined GIST
Hong Kong's Department of Health approved the agent for patients with advanced, PDGFRA D842V-mutated gastrointestinal stromal tumors.
Blueprint Medicines Reports $24.2M in Q3 Revenues Driven by Ayvakit Sales
Q3 revenues were down by 97 percent year over year because Blueprint's Q3 2020 revenues were bolstered by a licensing agreement with Roche for the RET inhibitor Gavreto.